Physician profile
Thomas R Blom
NPI 1932304599
$677.30
in general payments reported to CMS, 2019-2025
15 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $13.04 · 2021: $21.63 · 2022: $41.27 · 2023: $47.36 · 2024: $135 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.18 |
| Education | $115.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $144.50 | 2019 | |
| Gilead Sciences, INC. | $103.47 | 2024-2025 | Trodelvy |
| Janssen Biotech, INC. | $76.56 | 2022-2025 | Talvey, Tecvayli |
| Incyte Corporation | $66.95 | 2023-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Janssen Pharmaceuticals, INC | $41.52 | 2019-2024 | Xarelto |
| Tempus Ai, INC | $38.41 | 2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $31.86 | 2025 | |
| Merck Sharp & Dohme LLC | $28.90 | 2019-2023 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $21.63 | 2021 | |
| Beone Medicines USA, INC. | $20.42 | 2025 | Tevimbra |
| Glaxosmithkline, LLC. | $16.69 | 2025 | Blenrep |
| Daiichi Sankyo INC. | $16.41 | 2023 | Injectafer |
| Celgene Corporation | $13.69 | 2025 | Reblozyl |
| Pfizer INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Blom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.